A Symposium: Maximizing Therapeutic Outcomes in the Management of Acute Ischemic Coronary SyndromesWHITE, Harvey D.The American journal of cardiology. 1997, Vol 80, Num 4A, issn 0002-9149, 51 p.Conference Proceedings

A new definition of MI: what does it mean?WHITE, Harvey D.Current therapeutics. 2002, Vol 43, Num 6, pp 55-58, issn 0311-905XArticle

Management of patients with non-ST-elevation acute coronary syndromes : Cardiovascular Disease ManagementWHITE, Harvey D.Current therapeutics. 2001, pp 52-57, issn 0311-905X, SUP15Article

Oral antiplatelet therapy for atherothrombotic disease: Current evidence and new directionsWHITE, Harvey D.The American heart journal. 2011, Vol 161, Num 3, pp 450-461, issn 0002-8703, 12 p.Article

Using Zip Code-Level Mortality Data as a Local Health Status Indicator in Mobile, Alabama : Proceedings of the 2006 and 2007 University of South Alabama center for healthy communities regional health disparities symposiumARRIETA, Martha; WHITE, Harvey L; CROOK, Errol D et al.The American journal of the medical sciences. 2008, Vol 335, Num 4, pp 271-274, issn 0002-9629, 4 p.Article

Strategies for evaluation thrombolytic therapy, December 5, 1991ALPERT, Joseph S; WHITE, Harvey D.The American journal of cardiology. 1991, Vol 68, Num 16, issn 0002-9149, 47 E pConference Proceedings

Thrombolysis, anticoagulation, and reocclusionRAPAPORT, E.The American journal of cardiology. 1991, Vol 68, Num 16, pp 17E-22E, issn 0002-9149Conference Paper

Rivaroxaban for the treatment of acute coronary syndromesWONG, Cheuk-Kit; WHITE, Harvey D.Expert opinion on pharmacotherapy. 2013, Vol 14, Num 7, pp 917-927, issn 1465-6566, 11 p.Article

The HERO-2 ECG sub-studies in patients with ST elevation myocardial infarction: Implications for clinical practiceWONG, Cheuk-Kit; WHITE, Harvey D.International journal of cardiology. 2013, Vol 170, Num 1, pp 17-23, issn 0167-5273, 7 p.Article

Bivalirudin pharmacokinetics and pharmacodynamics: Effect of renal function, dose, and genderROBSON, Richard; WHITE, Harvey; AYLWARD, Philip et al.Clinical pharmacology and therapeutics. 2002, Vol 71, Num 6, pp 433-439, issn 0009-9236Article

A symposium: anticoagulant therapy: new promises and challengesTOPOL, Eric J; WHITE, Harvey D.The American journal of cardiology. 1998, Vol 82, Num 8B, issn 0002-9149, 71 p.Conference Proceedings

Acute myocardial infarctionWHITE, Harvey D; CHEW, Derek P.Lancet (British edition). 2008, Vol 372, Num 9638, pp 570-584, issn 0140-6736, 15 p.Article

Coronary disease clinical implications of the new definition of myocardial infarctionFRENCH, John K; WHITE, Harvey D.Heart (London 1996). 2004, Vol 90, Num 1, pp 99-106, issn 1355-6037, 8 p.Article

Impact of eptifibatide on early ischemic events in acute ischemic coronary syndromes : A review of the impact II trialTCHENG, J. E.The American journal of cardiology. 1997, Vol 80, Num 4A, pp 21B-28B, issn 0002-9149Conference Paper

Design and methodology of the PURSUIT trial: Evaluating of acute ischemic coronary syndromesHARRINGTON, R. A.The American journal of cardiology. 1997, Vol 80, Num 4A, pp 34B-38B, issn 0002-9149Conference Paper

We must use the knowledge that we have to treat patients with acute coronary syndromesWHITE, Harvey D; WILLERSON, James T.Circulation (New York, N.Y.). 2004, Vol 109, Num 6, pp 698-700, issn 0009-7322, 3 p.Article

Primary and secondary safety endpoints from IMPACT IIKLEIMAN, N. S.The American journal of cardiology. 1997, Vol 80, Num 4A, pp 29B-33B, issn 0002-9149Conference Paper

Unmet therapeutic needs in the management of acute ischemiaWHITE, H. D.The American journal of cardiology. 1997, Vol 80, Num 4A, pp 2B-10B, issn 0002-9149Conference Paper

Coronary intervention for persistent occlusion after myocardial infarctionHOCHMAN, Judith S; LAMAS, Gervasio A; SADOWSKI, Zygmunt et al.The New England journal of medicine. 2006, Vol 355, Num 23, pp 2395-2407, issn 0028-4793, 13 p.Article

Relationship between lipid levels and clinical outcomes in the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID): Trial to what extent is the reduction in coronary events with Pravastatin explained by on-study lipid levels?SIMES, R. John; MARSCHNER, Ian C; SHAW, John et al.Circulation (New York, N.Y.). 2002, Vol 105, Num 10, pp 1162-1169, issn 0009-7322Article

Antiplatelet drug nonresponsivenessGLADDING, Patrick; WEBSTER, Mark; ORMISTON, John et al.The American heart journal. 2008, Vol 155, Num 4, pp 591-599, issn 0002-8703, 9 p.Article

Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes : benefit and harm in different age subgroupsHERNANDEZ, Adrian V; WESTERHOUT, Cynthia M; WALLENTIN, Lars C et al.Heart (London 1996). 2007, Vol 93, Num 4, pp 450-455, issn 1355-6037, 6 p.Article

Predictors of stroke within 30 days in patients with non-ST-segment elevation acute coronary syndromesWESTERHOUT, Cynthia M; HERNANDEZ, Adrian V; SIMOONS, Maarten L et al.European heart journal. 2006, Vol 27, Num 24, pp 2956-2961, issn 0195-668X, 6 p.Article

The clinical profile of patients with suspected cardiogenic shock due to predominant left ventricular failure : A report from the SHOCK Trial RegistryMENON, Venu; WHITE, Harvey; LEJEMTEL, Thierry et al.Journal of the American College of Cardiology. 2000, Vol 36, Num 3, pp 1071-1076, issn 0735-1097, SUPAArticle

A randomized trial evaluating the effects of change in dairy food consumption on cardio-metabolic risk factorsBENATAR, Jocelyne R; JONES, Emma; WHITE, Harvey et al.European journal of preventive cardiology (Print). 2014, Vol 21, Num 11, pp 1376-1386, issn 2047-4873, 11 p.Article